Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 13, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.0K

Oligometastatic Prostate Cancer.

Daniel J Stevens1, Prasanna Sooriakumaran2

  • 1Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Room 6607, Level 6, Headington, Oxford, OX3 9DU, UK.

Current Treatment Options in Oncology
|October 28, 2016
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radical Prostatectomy in Low-volume Metastatic Prostate Cancer? The Need for New Evidence.

European urology·2026
Same author

AI based prediction of post prostatectomy urinary incontinence and its impact on quality of life: development and validation study.

Scientific reports·2026
Same author

A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [<sup>177</sup>Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation.

Nuclear medicine and biology·2025
Same author

Retzius-sparing robot-assisted radical prostatectomy in renal transplant recipients.

BJU international·2025
Same author

Retzius-Sparing Robot-Assisted Radical Prostatectomy.

Journal of endourology·2025
Same author

An international consensus panel on the potential value of Digital Surgery.

BMJ open·2024
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Men with limited metastatic prostate cancer may benefit from radical treatment of the primary tumor and metastasis-directed therapy. This approach, however, requires careful patient selection and is best performed at high-volume centers while awaiting definitive trial results.

Area of Science:

  • Oncology
  • Urology
  • Cancer Treatment

Background:

  • Current standard treatment for men with limited metastatic prostate cancer (≤3 lesions) is palliative androgen deprivation therapy (ADT).
  • ADT is associated with significant morbidity.
  • Retrospective data suggest potential survival benefits with more aggressive local treatment strategies.

Purpose of the Study:

  • To evaluate the potential survival benefit of combining radical treatment of the primary prostate tumor with metastasis-directed therapy (MDT) for select patients.
  • To highlight the importance of patient selection and specialized centers for this treatment approach.

Main Methods:

  • Review of retrospective literature.
  • Analysis of outcomes in patients undergoing combined radical prostatectomy/radiation and MDT versus ADT alone.
Keywords:
OligometastaticProstate cancer

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

7.1K

Related Experiment Videos

Last Updated: Mar 13, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.0K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

7.1K
  • Emphasis on quality assurance and high-volume center data.

    • Main Results:

    • Retrospective data suggest a survival benefit for radical primary tumor treatment plus MDT in men with limited metastatic disease.
    • This combined approach requires careful consideration due to potential uncertainties in benefit.

    Conclusions:

    • Radical treatment of the primary tumor combined with metastasis-directed therapy may offer a survival advantage for men with limited metastatic prostate cancer.
    • This strategy should be reserved for high-volume centers with robust quality assurance.
    • Further evidence from randomized controlled trials is needed to confirm these findings.